BioWorld Asia

Nov. 26, 2003

Failing To Find Buyer, Celltech To Close OGS's Proteomics Business

LONDON - Celltech Group plc announced it is closing Oxford GlycoSciences plc's flagship proteomics business, after failing to find a buyer for the unit, which it acquired when it took over Oxford GlycoSciences in April. (BioWorld International) Read More

Intercell Raises $20M, Tops $100M in Venture Backing

Lymphatic Vessel Growth Factor Nears Clinical Trial Development

CeNeS Buying TheraSci In All-Share Deal Worth $6.3M

Peptech Settles License Dispute Concerning Abbott Labs' Humira

Ester Neuroscience's MG Drug Gets FDA Orphan Drug Status

As Part Of Deal, ExonHit Delivers Small-Molecule Target to Allergan

EU Parliament Grants Permissive Approach To Stem Cell Research

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...